CSIMarket Company Name, Ticker, Suppliers, else..
 
Absci Corp  (NASDAQ: ABSI)
Other Ticker:  
 
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $3.1000 $0.09 2.990%
Day's High: $3.16 Week Perf: 0.65 %
Day's Low: $ 3.06 30 Day Perf: -37.5 %
Volume (M): 3,015 52 Wk High: $ 6.72
Volume (M$): $ 9,346 52 Wk Avg: $4.00
Open: $3.11 52 Wk Low: $2.45



 Market Capitalization (Millions $) 340
 Shares Outstanding (Millions) 110
 Employees 126
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -103
 Cash Flow (TTM) (Millions $) -31
 Capital Exp. (TTM) (Millions $) 0

Absci Corp
Absci Corp is a biotechnology firm based in Vancouver, Canada. The company specializes in developing advanced technology platforms for the discovery and production of biotherapeutics, such as antibodies and vaccines. Their proprietary synthetic biology platform allows for rapid and high-throughput production of various biologics for research, clinical trials, and commercialization. Absci Corp's cutting-edge technologies enable the acceleration of drug development timelines and provide cost-effective solutions for biomanufacturing. The company is dedicated to advancing the field of biotechnology and improving healthcare outcomes through innovation and collaboration.


   Company Address: 18105 SE Mill Plain Blvd Vancouver 98683 WA
   Company Phone Number: 949-1041   Stock Exchange / Ticker: NASDAQ ABSI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
FTRE   -2.49%    
INCY        4.63% 
AMGN   -1.34%    
ILMN        3.36% 
MRNA        1.06% 
REGN   -0.6%    
• View Complete Report
   



Announcement

Abscis Bold Moves Innovations in Biotech and Revenue Growth Amid Financial Turbulence,

Published Sun, Dec 29 2024 11:06 PM UTC

In an era defined by rapid advancements in biotechnology, Absci Corporation is making significant strides that could alter the landscape of therapeutic development. At their recent 2024 Research and Development (R&D) Day, the company showcased promising updates from their proprietary pipeline, particularly with a new drug candidate, ABS-201 an innovative anti-Growth Hormone ...
Stock Market Announcement

Absci Corporation Grants Stock Options to Chief Legal Officer: Paving the Way for Growth and Innovation in AI Drug Discovery

Published Wed, Jul 3 2024 8:00 PM UTC

Absci Corporation Grants Stock Options to Chief Legal Officer: Impact on Shareholders and Company Performance
VANCOU...
Absci Corp

Mysterious Decline: Absci Corp's Revenue Plummets in Fiscal Q3 2024

Absci Corporation, a data-first generative AI drug creation company, recently reported its financial results for the fiscal period of January to March 31, 2024. The company showcased some improvements, although it faced a decline in revenue compared to the previous year.
During this fiscal period, Absci Corp managed to decrease its loss per share to $-0.22, which is an improvement compared to the $-0.26 loss per share reported a year ago. Additionally, the company's EPS showed improvement, rising from $-0.25 per share in the previous reporting season.
Absci Corp

Absci Corp Takes a Financial Hit: Revenue Plummets by 78% in Fourth Quarter

Investors Beware: ABSI Reports Disastrous Fourth Quarter of 2023 Financial Results
Absci Corp (Nasdaq: ABSI) recently released its fourth quarter of 2023 financial report, and the numbers are painting a bleak picture for the company. Revenue took a nosedive, fading by a staggering -78.292% to just $0.34 million, while the net loss per share swelled to $-0.25, compared to $-0.24 in the previous reporting season. Additionally, revenue tumbled sequentially by -54.57% from the preceding quarter, dropping from $0.74 million.
The fourth quarter of 2023 earnings season saw Absci Corp realize a net loss of $-23.545 million, a significant increase from $-19.471 million in the same period a year ago. The company also experienced a buildup in accounts receivable, signaling rising demand, with accounts receivables valued at $2.2 million, higher than in the preceding quarter.
Stock Market Announcement

Absci Corp Surges After Closing Highly Successful Public Offering, Strengthening AI Drug Creation Capabilities

Published Fri, Mar 1 2024 9:01 PM UTC

Extensive Absci Announces Successful Closure of Public Offering of Common Stock, Boosting Investor Confidence and Funding for AI Drug Creation
VANCOUVER, Wash., March 01, 2024 - Absci Corporation (Nasdaq: ABSI), a leading data-first generative AI drug creation company, has recently concluded its underwritten public offering of 19,205,000 shares of common stock at a pric...






Absci's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com